Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95116

1.

Diffusion-weighted imaging of prostate cancer using a statistical model based on the gamma distribution.

Shinmoto H, Oshio K, Tamura C, Soga S, Okamura T, Yamada K, Kaji T, Mulkern RV.

J Magn Reson Imaging. 2014 Sep 15. doi: 10.1002/jmri.24761. [Epub ahead of print]

PMID:
25223894
[PubMed - as supplied by publisher]
2.

Magnetic Resonance Perfusion Characteristics of Hypervascular Renal and Hypovascular Prostate Spinal Metastases: Clinical Utilities and Implications.

Saha A, Peck KK, Lis E, Holodny AI, Yamada Y, Karimi S.

Spine (Phila Pa 1976). 2014 Aug 14. [Epub ahead of print]

PMID:
25188594
[PubMed - as supplied by publisher]
3.

Radium-223 dichloride for the treatment of metastatic prostate cancer.

Turner PG, O'Sullivan J.

Expert Opin Pharmacother. 2014 Oct;15(14):2105-11. doi: 10.1517/14656566.2014.955016. Epub 2014 Sep 4.

PMID:
25186336
[PubMed - in process]
4.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

PMID:
25184630
[PubMed - indexed for MEDLINE]
5.

Targeting the androgen receptor in prostate cancer--a resilient foe.

Nelson PS.

N Engl J Med. 2014 Sep 11;371(11):1067-9. doi: 10.1056/NEJMe1409306. Epub 2014 Sep 3. No abstract available.

PMID:
25184629
[PubMed - indexed for MEDLINE]
6.

Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature.

Di Meglio A, Nuzzo PV, Ricci F, Spina B, Boccardo F.

BMC Cancer. 2014 Aug 26;14:613. doi: 10.1186/1471-2407-14-613.

PMID:
25159097
[PubMed - in process]
Free PMC Article
7.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2014 Aug 20. pii: S0302-2838(14)00752-0. doi: 10.1016/j.eururo.2014.08.010. [Epub ahead of print]

PMID:
25151013
[PubMed - as supplied by publisher]
8.

Fungal prostatitis: an update.

Mayayo E, Fernández-Silva F.

Anal Quant Cytopathol Histpathol. 2014 Jun;36(3):167-76.

PMID:
25141493
[PubMed - indexed for MEDLINE]
9.

Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice.

Adamczyk P, Wolski Z, Butkiewicz R, Nussbeutel J, Drewa T.

Cent European J Urol. 2014;67(2):136-41. doi: 10.5173/ceju.2014.02.art4. Epub 2014 Jun 23.

PMID:
25140226
[PubMed]
Free PMC Article
10.

Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer--reply.

Pisansky TM, Bruner DW, Greenberg RE.

JAMA. 2014 Aug 20;312(7):748-9. doi: 10.1001/jama.2014.7923. No abstract available.

PMID:
25138339
[PubMed - indexed for MEDLINE]
11.

Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer.

Castiglione F, Montorsi F, Briganti A.

JAMA. 2014 Aug 20;312(7):748. doi: 10.1001/jama.2014.7920. No abstract available.

PMID:
25138338
[PubMed - indexed for MEDLINE]
12.

Nurses support prostate cancer drug appeal.

[No authors listed]

Nurs Times. 2014 Jul 16-22;110(29):4. No abstract available.

PMID:
25137936
[PubMed - indexed for MEDLINE]
13.

Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.

Stimac G, Spajic B, Reljic A, Katusic J, Popovic A, Grubisic I, Tomas D.

Korean J Urol. 2014 Aug;55(8):527-32. doi: 10.4111/kju.2014.55.8.527. Epub 2014 Aug 8.

PMID:
25132947
[PubMed - in process]
Free PMC Article
14.

The cistrome and gene signature of androgen receptor splice variants in castration-resistant prostate cancer cells.

Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJ.

J Urol. 2014 Aug 14. pii: S0022-5347(14)04214-1. doi: 10.1016/j.juro.2014.08.043. [Epub ahead of print]

PMID:
25132238
[PubMed - as supplied by publisher]
15.

[Roles of medical oncologists in the new era of CRPC therapy in Japan].

Takahashi S.

Gan To Kagaku Ryoho. 2014 Jul;41(7):827-31. Japanese.

PMID:
25131868
[PubMed - indexed for MEDLINE]
16.

[Role of urologists in the era of new treatment modalities for CRPC in Japan].

Ozono S.

Gan To Kagaku Ryoho. 2014 Jul;41(7):823-6. Japanese.

PMID:
25131867
[PubMed - indexed for MEDLINE]
17.

[Cabazitaxel-a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].

Ecstein-Fraisse E, Su Z.

Gan To Kagaku Ryoho. 2014 Jul;41(7):817-22. Japanese.

PMID:
25131866
[PubMed - indexed for MEDLINE]
18.

[Abiraterone acetate(ZYTIGA®)-development and literature review].

Nishimura Y, Mukai H, Suzukawa K, Oyama R.

Gan To Kagaku Ryoho. 2014 Jul;41(7):811-6. Japanese.

PMID:
25131865
[PubMed - indexed for MEDLINE]
19.

[Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].

Maeda H, Saito A.

Gan To Kagaku Ryoho. 2014 Jul;41(7):805-10. Japanese.

PMID:
25131864
[PubMed - indexed for MEDLINE]
20.

[New era of the treatment of CRPC in Japan].

Akaza H.

Gan To Kagaku Ryoho. 2014 Jul;41(7):804. Japanese.

PMID:
25131863
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk